HeartSciences Inc Financials
Financial Health Signals
Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores
HeartSciences Inc has an operating margin of -192013.1%, meaning the company retains $-192013 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is down from -33902.0% the prior year.
HeartSciences Inc's revenue declined 76.6% year-over-year, from $19K to $4K. This contraction results in a growth score of 0/100.
HeartSciences Inc carries a low D/E ratio of 1.05, meaning only $1.05 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 72/100, indicating a strong balance sheet with room for future borrowing.
HeartSciences Inc's current ratio of 1.47 indicates adequate short-term liquidity, earning a score of 39/100. The company can meet its near-term obligations, though with limited headroom.
While HeartSciences Inc generated -$7.4M in operating cash flow, capex of $3K consumed most of it, leaving -$7.4M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.
HeartSciences Inc passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.
For every $1 of reported earnings, HeartSciences Inc generates $0.85 in operating cash flow (-$7.4M OCF vs -$8.8M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
HeartSciences Inc earns $-16.7 in operating income for every $1 of interest expense (-$8.4M vs $500K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
This page shows HeartSciences Inc (HSCS) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 4 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Key Financial Metrics
HeartSciences Inc generated $4K in revenue in fiscal year 2025. This represents a decrease of 76.6% from the prior year.
HeartSciences Inc's EBITDA was -$8.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 32.4% from the prior year.
HeartSciences Inc generated -$7.4M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 20.9% from the prior year.
HeartSciences Inc reported -$8.8M in net income in fiscal year 2025. This represents a decrease of 32.7% from the prior year.
HeartSciences Inc earned $-9.34 per diluted share (EPS) in fiscal year 2025. This represents an increase of 50.2% from the prior year.
HeartSciences Inc held $2.8M in cash against $0 in long-term debt as of fiscal year 2025.
HeartSciences Inc had 2M shares outstanding in fiscal year 2025. This represents an increase of 126.0% from the prior year.
HeartSciences Inc's gross margin was 56.8% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 10.5 percentage points from the prior year.
HeartSciences Inc's operating margin was -192013.1% in fiscal year 2025, reflecting core business profitability. This is down 158111.1 percentage points from the prior year.
HeartSciences Inc's net profit margin was -201499.5% in fiscal year 2025, showing the share of revenue converted to profit. This is down 165987.6 percentage points from the prior year.
HeartSciences Inc invested $4.4M in research and development in fiscal year 2025. This represents an increase of 52.4% from the prior year.
HeartSciences Inc invested $3K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 95.1% from the prior year.
HSCS Income Statement
| Metric | Q2'25 | Q1'25 | Q3'25 | Q2'24 | Q1'24 | Q3'24 | Q2'23 | Q1'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2K+27.3% | $2K | N/A | N/A | N/A | $15K+276.9% | $4K | N/A |
| Cost of Revenue | $1K+32.6% | $760 | N/A | N/A | N/A | $5K+200.1% | $2K | N/A |
| Gross Profit | $1K+23.8% | $1K | N/A | N/A | N/A | $10K+326.0% | $2K | N/A |
| R&D Expenses | $727K-27.1% | $997K-3.5% | $1.0M-13.8% | $1.2M-2.1% | $1.2M+140.4% | $510K-32.7% | $757K+33.9% | $566K |
| SG&A Expenses | $1.3M+53.5% | $878K-34.4% | $1.3M+70.3% | $786K-7.6% | $851K-17.1% | $1.0M+25.9% | $815K+6.5% | $765K |
| Operating Income | -$2.1M-10.6% | -$1.9M+21.0% | -$2.4M-19.5% | -$2.0M+4.4% | -$2.1M-36.1% | -$1.5M+2.8% | -$1.6M-18.0% | -$1.3M |
| Interest Expense | $280K+52.2% | $184K+2.3% | $179K+52.6% | $118K+422.1% | $23K-81.0% | $118K-33.6% | $178K+392.1% | $36K |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$2.4M-14.4% | -$2.1M+19.0% | -$2.5M-21.8% | -$2.1M-1.5% | -$2.1M-24.8% | -$1.6M+6.0% | -$1.7M-27.9% | -$1.4M |
| EPS (Diluted) | $-0.85+46.2% | $-1.58+38.5% | $-2.57-13.2% | $-2.27+14.0% | $-2.64 | $-3.01+81.1% | $-15.92-20.3% | $-13.23 |
HSCS Balance Sheet
| Metric | Q2'25 | Q1'25 | Q3'25 | Q2'24 | Q1'24 | Q3'24 | Q2'23 | Q1'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $6.0M-6.9% | $6.4M+12.9% | $5.7M-26.7% | $7.8M-5.1% | $8.2M-24.2% | $10.8M+356.0% | $2.4M-8.8% | $2.6M |
| Current Assets | $3.8M-14.1% | $4.4M+21.7% | $3.6M-36.2% | $5.7M-6.3% | $6.1M-30.1% | $8.7M+379.6% | $1.8M-10.7% | $2.0M |
| Cash & Equivalents | $2.0M-30.1% | $2.8M+7.5% | $2.6M-35.9% | $4.1M-6.6% | $4.3M-38.7% | $7.1M+6966.3% | $100K-82.6% | $576K |
| Inventory | $657K+1.2% | $650K-0.4% | $652K-0.1% | $653K+1.5% | $643K-4.1% | $670K-0.7% | $675K-0.2% | $676K |
| Accounts Receivable | $4K | N/A | N/A | N/A | N/A | $15K+276.9% | $4K | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $1.8M-45.0% | $3.3M-15.9% | $3.9M+4.2% | $3.8M+66.6% | $2.3M+4.2% | $2.2M-46.1% | $4.0M+28.9% | $3.1M |
| Current Liabilities | $1.6M-48.0% | $3.0M-15.6% | $3.6M+8.1% | $3.3M+144.3% | $1.4M-20.8% | $1.7M-51.7% | $3.5M+86.1% | $1.9M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $4.2M+33.2% | $3.1M+75.8% | $1.8M-55.5% | $4.0M-32.3% | $5.9M-31.3% | $8.6M+623.4% | -$1.6M-217.4% | -$520K |
| Retained Earnings | -$80.5M-3.0% | -$78.2M-5.6% | -$74.0M-3.5% | -$71.5M-3.0% | -$69.4M-5.9% | -$65.5M-2.6% | -$63.9M-2.8% | -$62.1M |
HSCS Cash Flow Statement
| Metric | Q2'25 | Q1'25 | Q3'25 | Q2'24 | Q1'24 | Q3'24 | Q2'23 | Q1'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$2.3M-19.5% | -$2.0M-20.6% | -$1.6M+25.8% | -$2.2M-8.2% | -$2.0M+3.9% | -$2.1M-112.6% | -$988K+29.6% | -$1.4M |
| Capital Expenditures | $0 | N/A | $0 | N/A | $49K+454.9% | $9K+350.5% | $2K-60.2% | $5K |
| Free Cash Flow | -$1.6M | N/A | -$1.6M | N/A | -$1.6M+23.0% | -$2.1M-113.1% | -$990K+29.7% | -$1.4M |
| Investing Cash Flow | -$16K-1837.3% | -$814+94.8% | -$16K-168.8% | -$6K-601.3% | -$833+98.3% | -$49K-2419.5% | -$2K+60.2% | -$5K |
| Financing Cash Flow | $1.5M-58.6% | $3.6M+1924.7% | $180K-90.5% | $1.9M+244.7% | $552K-94.0% | $9.1M+1673.4% | $515K+58.7% | $324K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
HSCS Financial Ratios
| Metric | Q2'25 | Q1'25 | Q3'25 | Q2'24 | Q1'24 | Q3'24 | Q2'23 | Q1'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 58.3%-1.7pp | 60.0% | N/A | N/A | N/A | 69.0%+7.9pp | 61.0% | N/A |
| Operating Margin | -85713.2%+12924.6pp | -98637.8% | N/A | N/A | N/A | -10376.8%+29878.2pp | -40255.0% | N/A |
| Net Margin | -97179.4%+10978.2pp | -108157.6% | N/A | N/A | N/A | -11182.4%+33647.8pp | -44830.2% | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -39.2%-7.3pp | -31.9%+12.6pp | -44.5%-17.7pp | -26.8%-1.7pp | -25.1%-9.8pp | -15.2%+58.6pp | -73.8%-21.2pp | -52.6% |
| Current Ratio | 2.42+1.0 | 1.47+0.4 | 1.02-0.7 | 1.72-2.8 | 4.49-0.6 | 5.09+4.6 | 0.51-0.6 | 1.07 |
| Debt-to-Equity | 0.43-0.6 | 1.05-1.1 | 2.19+1.3 | 0.94+0.6 | 0.38+0.1 | 0.25+2.7 | -2.44+3.6 | -6.00 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | -14352.1%+11036.0pp | -25388.2% | N/A |
Similar Companies
Frequently Asked Questions
What is HeartSciences Inc's annual revenue?
HeartSciences Inc (HSCS) reported $4K in total revenue for fiscal year 2025. This represents a -76.6% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is HeartSciences Inc's revenue growing?
HeartSciences Inc (HSCS) revenue declined by 76.6% year-over-year, from $19K to $4K in fiscal year 2025.
Is HeartSciences Inc profitable?
No, HeartSciences Inc (HSCS) reported a net income of -$8.8M in fiscal year 2025, with a net profit margin of -201499.5%.
What is HeartSciences Inc's earnings per share (EPS)?
HeartSciences Inc (HSCS) reported diluted earnings per share of $-9.34 for fiscal year 2025. This represents a 50.2% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is HeartSciences Inc's EBITDA?
HeartSciences Inc (HSCS) had EBITDA of -$8.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is HeartSciences Inc's gross margin?
HeartSciences Inc (HSCS) had a gross margin of 56.8% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is HeartSciences Inc's operating margin?
HeartSciences Inc (HSCS) had an operating margin of -192013.1% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is HeartSciences Inc's net profit margin?
HeartSciences Inc (HSCS) had a net profit margin of -201499.5% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is HeartSciences Inc's free cash flow?
HeartSciences Inc (HSCS) generated -$7.4M in free cash flow during fiscal year 2025. This represents a -20.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is HeartSciences Inc's operating cash flow?
HeartSciences Inc (HSCS) generated -$7.4M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are HeartSciences Inc's total assets?
HeartSciences Inc (HSCS) had $6.4M in total assets as of fiscal year 2025, including both current and long-term assets.
What are HeartSciences Inc's capital expenditures?
HeartSciences Inc (HSCS) invested $3K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does HeartSciences Inc spend on research and development?
HeartSciences Inc (HSCS) invested $4.4M in research and development during fiscal year 2025.
How many shares does HeartSciences Inc have outstanding?
HeartSciences Inc (HSCS) had 2M shares outstanding as of fiscal year 2025.
What is HeartSciences Inc's current ratio?
HeartSciences Inc (HSCS) had a current ratio of 1.47 as of fiscal year 2025, which is considered adequate.
What is HeartSciences Inc's debt-to-equity ratio?
HeartSciences Inc (HSCS) had a debt-to-equity ratio of 1.05 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is HeartSciences Inc's return on assets (ROA)?
HeartSciences Inc (HSCS) had a return on assets of -136.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is HeartSciences Inc's cash runway?
Based on fiscal year 2025 data, HeartSciences Inc (HSCS) had $2.8M in cash against an annual operating cash burn of $7.4M. This gives an estimated cash runway of approximately 5 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is HeartSciences Inc's Piotroski F-Score?
HeartSciences Inc (HSCS) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are HeartSciences Inc's earnings high quality?
HeartSciences Inc (HSCS) has an earnings quality ratio of 0.85x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can HeartSciences Inc cover its interest payments?
HeartSciences Inc (HSCS) has an interest coverage ratio of -16.7x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is HeartSciences Inc?
HeartSciences Inc (HSCS) scores 22 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.